Fatty Liver: Ang Tahimik na Banta

Fatty Liver: The Silent Threat You Can Stop

🎧 Listen to This Article (Tagalog and English audio available)

🔘 Filipino Audio

🔘 English Audio

All articles with Filipino audio can be found at this link:

• Filipino Audio

🟢 Introduction

Fatty liver disease is one of the most common yet often ignored health conditions today. Many people are unaware they have it—until it’s too late. The two audios here explain what a fatty liver is, why it develops, the problems it can cause, what to do if you already have it, and, most importantly, how to reverse it.

✅ To make this vital information more accessible, this article includes both English and Filipino audio versions. Whether you prefer listening in English or Tagalog, you can choose the audio that best fits your needs—or share it with loved ones who may benefit from it in either language.

The written article in English can be read at:

Fatty Liver: The Silent Threat You Can Stop.

Huwag Magkasakit! Don’t Get Sick!

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on Gab, Twitter (X), Facebook, at Telegram.

Kaugnay na mga Artikulo:

1. Filipino Audio
2. The Metabolic Syndrome
3. Diseases Associated with the Metabolic Syndrome
4. The 80/20 Rule Applied to Diseases
5. Cancers Associated with Metabolic Syndrome
6. Lung Diseases Associated with Metabolic Syndrome
7. The Deadliest Diseases Associated with Metabolic Syndrome
8. Abnormal Blood Clots and Metabolic Syndrome
9. Eye Problems and Metabolic Syndrome
10. Ear Problems and Metabolic Syndrome
11. Periodontal Disease and Metabolic Syndrome
12. Inflammation: Dolor, Tumor, Rubor, and Calor

Mga Batayan (References):

1. Younossi, Zobair M., et al. “Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes.” Hepatology, vol. 64, no. 1, 2016, pp. 73–84. Wiley Online Library, https://doi.org/10.1002/hep.28431.
2. Estes, Chris, et al. “Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.” Hepatology, vol. 67, no. 1, 2018, pp. 123–133. https://doi.org/10.1002/hep.29466.
3. Chalasani, Naga, et al. “The diagnosis and management of non‐alcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.” Hepatology, vol. 67, no. 1, 2018, pp. 328–357. https://doi.org/10.1002/hep.29367.
4. Schwimmer, Jeffrey B., et al. “Prevalence of fatty liver in children and adolescents.” Pediatrics, vol. 118, no. 4, 2006, pp. 1388–1393. https://doi.org/10.1542/peds.2006-1212.
5. Deng, Q., Lv, R., Zou, H. et al. Beneficial effects of intermittent fasting on nonalcoholic fatty liver disease: a narrative review. Egypt Liver Journal 14, 63 (2024). https://doi.org/10.1186/s43066-024-00368-x
6. Ouyang X, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008 Jun;48(6):993-9. doi: 10.1016/j.jhep.2008.02.011. Epub 2008 Mar 10. PMID: 18395287; PMCID: PMC2423467. https://pmc.ncbi.nlm.nih.gov/articles/PMC2423467/
7. Keating, Samuel E., et al. “Exercise and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.” Journal of Hepatology, vol. 57, no. 1, 2012, pp. 157–166. https://doi.org/10.1016/j.jhep.2012.02.023.
8. Rinella, Mary E. “Nonalcoholic Fatty Liver Disease: A Systematic Review.” JAMA, vol. 313, no. 22, 2015, pp. 2263–2273. https://doi.org/10.1001/jama.2015.5370.
9. Wong, Vincent Wai-Sun, et al. “Non‐Invasive Biomarkers in NAFLD and NASH—Current Progress and Future Promise.” Nature Reviews Gastroenterology & Hepatology, vol. 15, no. 8, 2018, pp. 461–478. https://doi.org/10.1038/s41575-018-0014-9.
10. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implicationsFrancque, Sven M. et al.Journal of Hepatology, Volume 65, Issue 2, 425 – 443. https://www.journal-of-hepatology.eu/article/S0168-8278(16)30107-6/fulltext
11. Newsome, Philip N., et al. “A Placebo‐Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.” New England Journal of Medicine, vol. 384, no. 12, 2021, pp. 1113–1124. https://doi.org/10.1056/NEJMoa2028395.

© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment

As an Amazon Associate, I earn from qualifying purchases.